+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis



Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis



Arthritis Care and Research 63(12): 1729-1735



To determine whether the presence of psoriatic arthritis (PsA) is associated with greater comorbidity, in particular cardiovascular morbidity, compared to psoriasis without arthritis. Six hundred eleven patients with PsA were recruited from the University of Toronto Psoriatic Arthritis Clinic and 449 psoriasis without arthritis patients were recruited from the University of Toronto Psoriasis Cohort. The clinical database was used to identify the prevalence of cardiovascular and other comorbidities in both PsA and psoriasis without arthritis patients. Univariate and multivariate logistic regression analyses were conducted to estimate odds ratios (ORs), comparing the odds of ever having a given comorbid disease in PsA patients with those in psoriasis without arthritis patients. Covariates included age, sex, education, smoking status, severity and duration of psoriasis, medication status, and other comorbidities. The prevalence of hypertension, obesity, hyperlipidemia, type 2 diabetes mellitus, and at least 1 cardiovascular event in PsA patients was 37.1%, 30.0%, 20.7%, 12.0%, and 8.2%, respectively. This was significantly higher than in psoriasis without arthritis patients, with unadjusted ORs ranging from 1.54 to 2.59. In the multivariate analyses, hypertension remained significantly elevated (adjusted OR 2.17). PsA was also significantly associated with infections not treated with antibiotics (presumably viral), neurologic conditions, gastrointestinal disorders, and liver disease (adjusted ORs 2.83, 4.76, 21.53, and 7.74, respectively). Infections treated with antibiotics and depression/anxiety were relatively common in PsA, with a prevalence of 30.5% and 20.7%, respectively. However, this was not significantly different from psoriasis without arthritis after multivariate adjustments. The results suggest that inflammatory joint disease may play a role in both cardiovascular and noncardiovascular morbidity in PsA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036198814

Download citation: RISBibTeXText

PMID: 21905258

DOI: 10.1002/acr.20627


Related references

Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. International Journal of Rheumatic Diseases 18(8): 873-879, 2015

Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross-sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires. Rheumatology International 36(2): 207-212, 2016

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology 31(6): 1021-1028, 2017

Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). British Journal of Dermatology 176(3): 765-770, 2017

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases 72(2): 211-216, 2013

AB1073Prevalence of Comorbidities in Early Stages of Inflammatory Arthritis: A Comparison of Two Cohorts of Patients with Rheumatoid Arthritis and Psoriatic Arthritis:. Annals of the Rheumatic Diseases 73(Suppl 2): 1156.1-1156, 2014

Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis A nationwide cohort study. 2012

Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. International Journal of Clinical Rheumatology 10(6): 451-459, 2015

Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. Journal of Rheumatology 40(8): 1434-1437, 2014

AB0588Prevalence of conventional cardiovascular risk factors in patients with psoriasis alone and in patients with psoriatic arthritis. Annals of the Rheumatic Diseases 72(Suppl 3): A969.3-A970, 2013

Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Archives of Dermatological Research 311(5): 351-360, 2019

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Journal of the European Academy of Dermatology and Venereology 33(2): 340-354, 2019

SAT0400Prevalence of Comorbidities in Patients with Psoriatic Arthritis and their Impact on Cardiovascular Risk and Quality of Life. Annals of the Rheumatic Diseases 73(Suppl 2): 739.2-739, 2014

Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care and Research 69(10): 1510-1518, 2017

AB0741Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique: Diagnostic Value for Detection of Subclinical Signs of Musculoskeletal Inflammation in Psoriasis?. Annals of the Rheumatic Diseases 75(Suppl 2): 1158.1-1158, 2016